๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Namdong-gu
Clinical trial register · South Korea

Clinical Trials in Namdong-gu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3364 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:49 UTC
3364
Studies in scope
all four open statuses
1829
Recruiting now
open to new participants
503
Lead sponsors
across recruiting studies
Top sites
Seoul 2820 Daegu 550 Seongnam-si 485 Busan 464 Goyang-si 395
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company14 Pfizer5 Hoffmann-La Roche3 AstraZeneca3 Loxo Oncology, Inc.3
Site location
Seoul2820 Daegu550 Seongnam-si485 Busan464 Goyang-si395
All 252 locations
Target enrolment
to

Trials with a site in Namdong-gu

34 of 3364 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
2,380
Ulsan, Goyang-si, Namdong-gu, Busan, Seoul, Bucheon-si, Goyang, Iksan
2026-12-16
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
DrugDonanemab
Eli Lilly and Company
Phase 2
350
Gangnam-gu, Incheon, Namdong-gu, Seoul
2026-05-20
Recruiting
Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)
NCT07318597Pulmonary Arterial Hypertension (PAH)
Regeneron Pharmaceuticals
Phase 2
99
Namdong-gu, Seoul
2026-05-06
Recruiting
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
NCT07405801Breast Cancer
DrugsInavolisib·Ribociclib·Fulvestrant
Hoffmann-La Roche
Phase 2
80
Dongnam-gu, Cheonan-si, Namdong-Gu, Seongnam-si, Seoul
2026-04-07
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
1,980
Namdong-gu, Seogu, Seongnam, Seoul, Yangsan
2026-02-06
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
2025-12-12
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease
DrugOrforglipron
Eli Lilly and Company
Phase 3
7,140
Bucheon-si, Busan, Daegu, Guri-si, Gwangju, Namdong-gu, Seongnam, Seoul
2025-12-01
Recruiting
A Study of Brenipatide in Participants With Alcohol Use Disorder
NCT07219953Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
NCT07219966Alcohol Use Disorder
DrugBrenipatide
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Daegu, Gwangju, Namdong-gu, Seongnam, Seoul, Suwon, Ulsan
2025-09-02
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Datopotamab Deruxtecan
AstraZeneca
Phase 2
278
Cheongju-si, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-08-07
Recruiting
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
NCT07013474COVID-19 Infection
DrugsIbuzatrelvir·Remdesivir
Pfizer
Phase 3
300
Namdong-gu, Gwangju, Seoul
2025-07-14
Recruiting
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
NCT07177352Alzheimers Disease
Hoffmann-La Roche
Phase 3
80,000
Gwangju, Gyeonggi-do, Incheon, Namdong-gu, Seongnam-si, Seoul, Suwon
2025-07-02
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Cheongju-si, Namdong-gu, Yangsan, Busan, Seoul
2025-04-24
Recruiting
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140COVID-19 SARS-CoV-2 Infection
DrugIbuzatrelvir
Pfizer
Phase 3
2,330
Namdong-gu, Tonggu, Wลnju, Gwangju, Ansan-si, Suwon, Dongjak-gu, Gangnam-gu
2024-12-08
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
DrugRemternetug
Eli Lilly and Company
Phase 3
1,400
Busan, Cheongju-si, Gangnam-gu, Gangseo-gu, Gwangju, Incheon, Jeju City, Namdong-gu
2024-10-24
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression โ‰ฅ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·5-FU·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Incheon, Namdong-gu, Seoul
2024-08-22
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Vinorelbine·Eribulin·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Cheonan-si, Namdong-gu, Seongnam-si, Seoul
2024-08-13
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
DrugsDatopotamab Deruxtecan·Osimertinib
AstraZeneca
Phase 3
582
Goyang-si, Namdong-gu, Seoul, Suwon
2024-04-29
Active, closed
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
DrugLepodisiran
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Active, closed
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903Obesity, Overweight, Overweight or Obesity
DrugOrforglipron
Eli Lilly and Company
Phase 3
3,127
Namdong-gu, Ansan-si, Anyang-si, Suwon, Busan, Seoul, Seogu
2023-06-05
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
Namdong-gu, Seoul
2023-03-16
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
DrugsVepdegestrant·Fulvestrant
Pfizer
Phase 3
624
Namdong-gu, Goyang-si, Seongnam, Suwon, Seoul
2023-03-03
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Namdong-gu, Hwasun Gun, Seongnam, Busan, Seoul, Daegu, Junggu
2022-03-25
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
DrugsImlunestrant·Exemestane·Abemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
874
Cheonan-si, Namdong-gu, Suwon, Daegu, Busan, Seoul
2021-10-04
Active, closed
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer
DrugsCMP 001·Utomilumab·Talazoparib·Axitinib
Pfizer
Phase 3
77
Namdong-gu, Goyang-si, Seongnam, Seoul
2021-09-29
Active, closed
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Pirtobrutinib
Loxo Oncology, Inc.
Phase 3
282
Namdong-gu, Seocho-Gu, Seoul, Busan
2021-09-23
Active, closed
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
NCT04961996Early Breast Cancer
DrugGiredestrant
Hoffmann-La Roche
Phase 3
4,170
Cheonan-si, Cheongju-si, Gangwon-do, Gyeonggi-do, Incheon, Namdong-Gu, Seongbuk-Gu, Seongnam
2021-08-27
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Namdong-gu, Seoul, Busan
2021-04-08
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine
Loxo Oncology, Inc.
Phase 3
238
Namdong-gu, Busan, Seocho-Gu, Seoul
2021-03-09
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Cheongju-si, Cheonan-si, Incheon, Namdong-gu, Goyang-si, Seongnam, Busan, Haeundae-gu
2017-07-12
Active, closed
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT02107703Breast Neoplasms
DrugsAbemaciclib·Fulvestrant
Eli Lilly and Company
Phase 3
669
Cheongju-si, Incheon, Namdong-gu, Seongnam, Seoul, Ulsan
2014-07-22
Rows per page Showing 1–34 of 34
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-south-korea/city/namdong-gu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,364 studies in total at the last sync on 26 Sep 2026, 19:49 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 34 of those studies with a site in Namdong-gu.

How many clinical trials are recruiting in Namdong-gu?

18 of the 34 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:49 UTC sync. A further 1 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Namdong-gu), 34 studies
PhaseStudiesRecruitingShare
Phase 3281382.4%
Phase 26517.6%

Most active sponsors

Lead sponsors with the most studies (Namdong-gu)
Lead sponsorStudiesRecruiting
Eli Lilly and Company147
Pfizer52
AstraZeneca33
Hoffmann-La Roche32
Loxo Oncology, Inc.30
Bristol-Myers Squibb21
Jazz Pharmaceuticals11
Merck Sharp & Dohme LLC10
Mirati Therapeutics Inc.11
Regeneron Pharmaceuticals11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.